Atea Pharmaceuticals
AVIR
AVIR
107 hedge funds and large institutions have $169M invested in Atea Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 45 increasing their positions, 30 reducing their positions, and 21 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less capital invested
Capital invested by funds: $ → $
less ownership
Funds ownership: →
9% less funds holding
Funds holding: 118 → 107 (-11)
48% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 21
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Holders
107
Holding in Top 10
1
Calls
$292K
Puts
$169K
Top Buyers
| 1 | +$3.82M | |
| 2 | +$2.02M | |
| 3 | +$1.68M | |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
+$1.45M |
| 5 |
Barclays
London,
United Kingdom
|
+$523K |
Top Sellers
| 1 | -$3.36M | |
| 2 | -$2.69M | |
| 3 | -$1.8M | |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$1.8M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$1.26M |